NRx Pharmaceuticals Q3 2026 Earnings Date & Estimates

NRx Pharmaceuticals (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly severe depression and suicidal ideation. The company’s research programs are designed to address conditions in which existing therapies may have limited effectiveness or delayed onset.

NRx’s lead investigational product is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for bipolar depression with acute suicidal ideation. The company has also evaluated related therapies, including NRX-100, an intravenous formulation of ketamine, in depression and suicidality-related treatment settings. These products remain investigational and require regulatory approval before they can be commercially marketed for new indications.

The company previously pursued ZYESAMI, an investigational formulation of aviptadil, as a potential treatment for critical COVID-19-related respiratory failure. NRx Pharmaceuticals was formed from NeuroRx and became publicly traded through a business combination with Big Rock Partners Acquisition Corp. in 2021. The company is headquartered in Radnor, Pennsylvania, and has been led by founder and Chief Executive Officer Jonathan Javitt, M.D., who has focused on the development of therapies for serious neurological and psychiatric conditions.